About Us | Contact

Nagaraj-Setty A Holalkere

Diagnostic Radiology Tufts Medical Center NPI1497881106
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$91,550.00
from 17 payments in the last 6 years

Total Cash or Cash Equivalent

$91,550.00
from 17 payments in the last 6 years

Total In-kind Items & Services

$0.00
from 0 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
09/29/2021 Research Cash or cash equivalent Biological $33940.00 Details
Payment from Roche Products Limited
Paymment Research Study PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS
Payment Record ID 835903251
10/29/2021 Research Cash or cash equivalent Biological $12550.00 Details
Payment from Roche Products Limited
Paymment Research Study PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS
Payment Record ID 835903245
08/20/2021 Research Cash or cash equivalent Biological $3150.00 Details
Payment from Roche Products Limited
Paymment Research Study PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS
Payment Record ID 835903239
06/24/2021 Research Cash or cash equivalent Biological $1070.00 Details
Payment from Roche Products Limited
Paymment Research Study PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS
Payment Record ID 835903233
04/15/2021 Research Cash or cash equivalent Biological $1600.00 Details
Payment from Roche Products Limited
Paymment Research Study PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS
Payment Record ID 835903227
02/18/2021 Research Cash or cash equivalent Biological $5810.00 Details
Payment from E.R. Squibb & Sons, L.L.C.
Paymment Research Study A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Clinical Trials Gov ID NCT02231749
Payment Record ID 819890325
08/12/2021 Research Cash or cash equivalent Biological $360.00 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Clinical Trials Gov ID NCT03409614
Payment Record ID 793082615
04/22/2021 Research Cash or cash equivalent Biological $3240.00 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Clinical Trials Gov ID NCT03409614
Payment Record ID 793082613
02/11/2021 Research Cash or cash equivalent Biological $11100.00 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Clinical Trials Gov ID NCT03409614
Payment Record ID 793082611
01/15/2021 Research Cash or cash equivalent Biological $700.00 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Clinical Trials Gov ID NCT03409614
Payment Record ID 793082609
12/28/2020 Research Cash or cash equivalent Biological $610.00 Details
Payment from E.R. Squibb & Sons, L.L.C.
Paymment Research Study A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Clinical Trials Gov ID NCT02231749
Payment Record ID 736765555
02/17/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $910.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405749286
01/08/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $5915.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405749280
04/20/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $2535.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405749128
04/20/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $2470.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405749126
01/21/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $4550.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405749118
05/18/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $1040.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405747672
;